Sanofi

Sanofi at forefront of fight against COVID-19 in Q1 2020 Rapid and decisive response to COVID-19 global health crisis Sanofi

FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination  Latest innovation in quadrivalent meningococcal vaccination designed for use in

 Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis Primary and secondary objectives

Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis *Sanofi to host virtual

 Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution Companies to negotiate a collaboration on the

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 Companies to combine innovative technologies to develop

COVID-19:  Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries  Sanofi to provide Plaquenil® (hydroxychloroquine) wherever possible, while

Paris – France – April 6, 2020 – Sanofi (EURONEXT: SAN and NASDAQ: SNY) announces that it has successfully priced

Sanofi finalizes Praluent® (alirocumab) restructuring with Regeneron Paris – April 6, 2020 – Sanofi has finalized the planned restructuring related

  Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995,

  Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995,

Information on Sanofi’s Shareholders General Meeting of Tuesday, April 28, 2020 Paris (France) – April 1st, 2020 - In view

First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19 Phase 2/3 trial

Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19 *The two companies will jointly investigate multiple

Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma Positive CHMP opinion

Sanofi successfully prices EUR 1.5 billion of bond issue Paris, France – March 24, 2020 - Sanofi (EURONEXT: SAN and

Filing of the 2019 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report   PARIS, France

 Paris (France) – March 4, 2020 - At its meeting on March 4, 2020, the Board of Directors of Sanofi

FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma Sarclisa in combination with pomalidomide and dexamethasone (pom-dex) significantly

Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*) New major API company1 would secure

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine *Work with Biomedical

Sanofi Completes Acquisition of Synthorx, Inc.  *Synthorx, Inc. is now a fully owned subsidiary of Sanofi PARIS (FRANCE) – January

Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency                  · Acid

Sanofi delivers strong 2019 business EPS growth of 6.8% at CER   Q4 2019 Change Change at CER 2019 Change

Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis  Sanofi’s BTK inhibitor will potentially